3q 14 vcchart

Page 1

Venture Capital Funding Survey, Third Quarter 2014

VENTURE CAPITAL FUNDING, THIRD QUARTER 2014 This is a listing of many of the Bay Area firms that received venture capital financing between July 1 and Sept 30, 2014. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with the Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups.

BIOTECHNOLOGY / HEALTH Name 3-V Biosciences

City Menlo Park

Stage Early Stage

Afferent Pharmaceuticals San Mateo

Early Stage

$2,700,000 Domain Associates, undisclosed firm

Clinical-stage biopharmaceutical company.

Airxpanders

Palo Alto

Expansion

$5,661,000 GBS Venture Partners, Prolog Ventures, Vivo Ventures

Breast cancer reconstruction.

Aldea Pharmaceuticals

Redwood City

Expansion

$9,263,000 Canaan Partners, Correlation Ventures, RusnanoMedInvest, undisclosed firms

Pharmaceutical company.

Allakos

San Carlos

Early Stage

Armetheon*

Menlo Park

Early Stage

Avinger

Redwood City

Expansion

$34,831,000 Lucas Venture Group

Biomimedica

South San Francisco South San Francisco

Early Stage

$250,000 Emergent Medical Partners $16,000,000 Advanced Technology Ventures, Delphi Ventures, Morgenthaler Ventures, T. Rowe Price Threshold Partnerships, undisclosed firms, Wellington Management

Calithera Biosciences

Early Stage

Amount Investors Description $3,499,000 Kleiner Perkins Caufield & Therapeutics that modulate Byers, New Enterprise pathways for the treatment Associates of oncology.

$15,000,000 Alta Partners, De Novo Ventures, F Hoffmann La Roche AG, RiverVest Venture Partners

Biotechnology company.

$7,000,000 AshHill Pharmaceutical Drugs for cardiovascular Investments, undisclosed diseases. firms

Page 1 of 21

Image-guided therapeutic devices. Medical device company. Therapeutics company.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.